| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5d1de0cb099ee72980dadb3b90d66d8 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-724
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-728
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-722
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00 |
| filingDate |
2005-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_560db4ae03737df5bb38801f3ca337a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1331499cc63d170edd2fe01dfe015745 |
| publicationDate |
2019-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2706848-T3 |
| titleOfInvention |
Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use |
| abstract |
A pharmaceutical composition comprising FGF18 and an IL-1 antagonist selected from the group consisting of: (i) IL-1ra, wherein said IL-1ra is selected from among a recombinant IL-1ra or an IL fusion protein -1ra, said fusion protein comprising the IL-1ra sequence shown in SEQ ID NO: 5 or an IL-1 inhibitor fragment thereof and a constant domain of a heavy chain or a light chain of human immunoglobulin in the amino terminus of said IL-1ra; or (ii) an anti-IL-1R1 antibody; wherein said pharmaceutical composition does not comprise hyaluronic acid. |
| priorityDate |
2004-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |